Clinical analysis of inhalable Seretide in the two-year treatment of patients with stable moderate COPD
10.3760/cma.j.issn.1008-6315.2012.02.001
- VernacularTitle:吸入舒利迭治疗稳定期中度慢性阻塞性肺疾病2年的临床分析
- Author:
Zhifang DOU
;
Qianhua CHEN
- Publication Type:Journal Article
- Keywords:
Stable chronic obstructive pulmonary difease;
Seretide;
Pulmonary function
- From:
Clinical Medicine of China
2012;28(2):113-115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of Seretide(50/250 μg)in the treatment of patients with stable moderate COPD.Methods Sixty-four patients in the stable period of moderate COPD were randomized into 2 groups,the test group and control group.The control group received routine treatment.The test group received the Seretide(50/250 μg)inhalation in addition to the routine treatment.During the 2-year observation,the pulmonary functions before and 12 and 24 months after treatment were recorded.The clinical symptoms,physical signs,the frequency of acute exacerbation of COPD and hospitaliztion duration were also graded.Results The difference of the parameters before and after the treatment was significant in the treatment group(P ＜0.01)but not in control group(P ＞0.05).The scores of symptoms and signs([2.1 ±0.4]vs.[4.4 ± 0.3],t =2.365),the frequency of acute exacerbation of COPD(29％ vs.47％,x2 =3.547)and hospitalization period ([5.0 ± 1.2]d vs.[10.0 ± 1.6]d,t =2.149)in the treatment group were significantly improved compared with control group after 24 months' treatment(all P ＜ 0.01).Conclusion Seretide(50/250 μg)is able to improve the lung function of the patients with stable moderate COPD and reduce the frequency of acute exacerbation,showing certain value in clinical practice.
